ethyl 2-((1H-indol-4-yl)oxy)acetate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-((1H-indol-4-yl)oxy)acetate
• 英文别名: Acetic acid, 2-(1H-indol-4-yloxy)-, ethyl ester；ethyl 2-(1H-indol-4-yloxy)acetate
• 化学式: C₁₂H₁₃NO₃
• 分子量: 219.24
• InChiKey: OGYYWFFUARJZKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  51.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-((1H-indol-4-yl)oxy)acetate 在 sodium cyanoborohydride 、 溶剂黄146 、 碳酸氢钠 作用下， 以 水 为溶剂， 反应 18.0h， 生成 ethyl 2-(indolin-4-yloxy)acetate
  参考文献：
  名称：

  WO2008/94922

  摘要：

  公开号：
• 作为产物：
  描述：

  4-羟基吲哚 、 溴乙酸乙酯 在 caesium carbonate 作用下， 以 乙腈 为溶剂， 反应 0.17h， 以63.5%的产率得到ethyl 2-((1H-indol-4-yl)oxy)acetate
  参考文献：
  名称：

  N-取代的吲哚衍生物作为新型Mcl-1抑制剂的发现及其构效关系研究。

  摘要：

  髓样细胞白血病1（Mcl-1）是一种重要的抗凋亡蛋白，通过蛋白-蛋白相互作用发挥功能。我们发现了带有新型N-取代的吲哚骨架的LSL-A6（2-（（2-氨基甲酰基-1-（3-（4-甲氧基苯氧基）丙基）-1H-吲哚-6-基）氧基）乙酸Mcl-1结合作为一种新型Mcl-1抑制剂。分子建模表明该化合物通过与P2和R263热点相互作用与Mcl-1结合。对吲哚核，疏水尾和酸性链等多个部分进行了结构修饰，并分析了结构-活性关系。经铅-铅修饰后，获得了最强的化合物24d，其显示出110nM的Ki值可干扰Mcl-1的结合。

  DOI：

  10.1016/j.bmcl.2017.03.028

文献信息

• Discovery and structure-activity relationship studies of N-substituted indole derivatives as novel Mcl-1 inhibitors
  作者：Shenglin Luan、Qi Ge、Yedong Chen、Mingyang Dai、Jinyu Yang、Kun Li、Dan Liu、Linxiang Zhao

  DOI：10.1016/j.bmcl.2017.03.028

  日期：2017.5

  acid) with a novel N-substituted indole scaffold to interfere Mcl-1 binding as a novel Mcl-1 inhibitor. Molecular modeling indicated that this compound binds with Mcl-1 by interaction with P2 and R263 hot-spots. Structure modification focused on several moieties including indole core, hydrophobic tail and acidic chain were conducted and structure-activity relationship was analyzed. The most potent compound

  髓样细胞白血病1（Mcl-1）是一种重要的抗凋亡蛋白，通过蛋白-蛋白相互作用发挥功能。我们发现了带有新型N-取代的吲哚骨架的LSL-A6（2-（（2-氨基甲酰基-1-（3-（4-甲氧基苯氧基）丙基）-1H-吲哚-6-基）氧基）乙酸Mcl-1结合作为一种新型Mcl-1抑制剂。分子建模表明该化合物通过与P2和R263热点相互作用与Mcl-1结合。对吲哚核，疏水尾和酸性链等多个部分进行了结构修饰，并分析了结构-活性关系。经铅-铅修饰后，获得了最强的化合物24d，其显示出110nM的Ki值可干扰Mcl-1的结合。
• Indole derivatives and their use as antibiotics
  申请人：Omnia Molecular, S. L.

  公开号：EP2639220A1

  公开（公告）日：2013-09-18

  Compound of formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof or a mixture of stereoisomers, which are useful as antibiotics. The invention also provides processes for the preparation of the compounds of formula (I) and intermediates, their compositions, their use as medicaments and methods for treating bacterial infections.

  化合物的化学式（I）或其药学上可接受的盐，或其立体异构体或立体异构体的混合物，这些化合物可用作抗生素。该发明还提供了制备化合物的方法（I）和中间体的方法，它们的组成，它们作为药物的用途以及治疗细菌感染的方法。
• PHOTOLABILE DINITROINDOLINYL BASED COMPOUNDS
  申请人：Ellis-Davies Graham

  公开号：US20100096252A1

  公开（公告）日：2010-04-22

  The present invention relates to photolabile or photoreleasable compounds including a caging moiety linked to an effector moiety, wherein the compounds are capable of releasing the effector moiety on irradiation, typically by flash irradiation with light. These compounds are particularly suitable for focal 2-photon uncaging The photoreleasable compounds can be used to deliver effector moieties such as carboxylic acids, preferably, neuroactive amino acids to sites where their activity is required. In preferred embodiments of the invention, the caging moiety is based on 4-carboxymethoxy-5,7-dinitroinlinyl and derivatives thereof.

  本发明涉及光敏可解离化合物或光释放化合物，包括与效应基团相连的笼合基团，其中该化合物能够在照射下释放效应基团，通常是通过光闪烁照射。这些化合物特别适用于局部2-光子解离。光释放化合物可用于将效应基团，如羧酸，优选地是神经活性氨基酸，输送到需要其活性的位置。在本发明的优选实施例中，笼合基团基于4-羧甲氧基-5,7-二硝基咪唑基和其衍生物。
• Photolabile dinitroindolinyl based compounds
  申请人：Ellis-Davies Graham

  公开号：US08642785B2

  公开（公告）日：2014-02-04

  The present invention relates to photolabile or photoreleasable compounds including a caging moiety linked to an effector moiety, wherein the compounds are capable of releasing the effector moiety on irradiation, typically by flash irradiation with UV light. These compounds are particularly suitable for focal 2-photon uncaging The photoreleasable compounds can be used to deliver effector moieties such as carboxylic acids, preferably, neuroactive amino acids to sites where their activity is required. In preferred embodiments of the invention, the caging moiety is based on 4-carboxymethoxy-5,7-dinitroinlinyl and derivatives thereof.

  本发明涉及光敏感或光释放化合物，包括与效应基团连接的笼罩基团，其中这些化合物能够通过紫外光闪光照射来释放效应基团。这些化合物特别适用于局部二光子解笼。光释放化合物可用于将效应基团（例如羧酸，优选为神经活性氨基酸）输送到需要其活性的位置。在本发明的优选实施例中，笼罩基团基于4-羧甲氧基-5,7-二硝基印胺及其衍生物。
• Structural Basis for the Structure−Activity Relationships of Peroxisome Proliferator-Activated Receptor Agonists
  作者：Neeraj Mahindroo、Yi-Hui Peng、Chia-Hui Lin、Uan-Kang Tan、Ekambaranellore Prakash、Tzu-Wen Lien、I-Lin Lu、Hong-Jen Lee、John Tsu-An Hsu、Xin Chen、Chun-Chen Liao、Ping-Chiang Lyu、Yu-Sheng Chao、Su-Ying Wu、Hsing-Pang Hsieh

  DOI：10.1021/jm060663c

  日期：2006.10.1

  Type 2 diabetes has rapidly reached an epidemic proportion becoming a major threat to global public health. PPAR agonists have emerged as a leading class of oral antidiabetic drugs. We report a structure biology analysis of novel indole-based PPAR agonists to explain the structure-activity relationships and present a critical analysis of reasons for change in selectivity with change in the orientation of the same scaffolds. The results would be helpful in designing novel PPAR agonists.